Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration

Results from the ASAS-COMOSPA Study

BRITSpA and COMOSPA Investigators

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Spondyloarthritis (SpA) is associated with a number of cardiovascular (CV) comorbidities. We examined the association of SpA disease duration and delay in diagnosis with CV-related conditions.

METHODS: Using data from the COMOSPA study, the associations between SpA disease duration and CV-related conditions were evaluated in univariable and multivariable logistic regression models. Each model examined 1 CV-related factor as dependent and "SpA disease duration" as a predictor, adjusted for relevant confounders.

RESULTS: Data from 3923 subjects (median SpA disease duration 5.1 yrs, interquartile range 1.3-11.8 yrs) were available for analysis. The main CV-related conditions were hypertension (HTN; 22.4%), ischemic heart disease (2.6%), stroke (1.3%), and diabetes mellitus (5.5%). HTN was associated with SpA disease duration in both univariable and multivariable analysis, with an OR of 1.129 (95% CI 1.072-1.189; p < 0.001) for each 5-year increase in SpA disease duration. Other factors associated with HTN were age, male sex, current body mass index, ever steroid therapy, and ever synthetic disease-modifying antirheumatic drug therapy, but not nonsteroidal antiinflammatory drugs (NSAID). In subgroup analysis, the strongest association of HTN and disease duration was seen in subjects with the axial-only SpA phenotype (OR 1.202, 95% CI 1.053-1.372) but not in those with peripheral-only SpA (OR 0.902, 95% CI 0.760-1.070). The other CV conditions were not associated with SpA disease duration.

CONCLUSION: Duration of SpA disease in the ASAS-COMOSPA cohort is associated with higher odds of HTN, particularly in those with axial disease, but not with other CV-related conditions. The association with HTN does not appear to be related to NSAID exposure.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalThe Journal of Rheumatology
Early online date15 Jan 2019
DOIs
Publication statusPublished - 31 Jan 2019

Cite this

Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration : Results from the ASAS-COMOSPA Study. / BRITSpA and COMOSPA Investigators.

In: The Journal of Rheumatology, 31.01.2019, p. 1-9.

Research output: Contribution to journalArticle

@article{1faa232db2f64869a4fb1295b16be910,
title = "Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration: Results from the ASAS-COMOSPA Study",
abstract = "OBJECTIVE: Spondyloarthritis (SpA) is associated with a number of cardiovascular (CV) comorbidities. We examined the association of SpA disease duration and delay in diagnosis with CV-related conditions.METHODS: Using data from the COMOSPA study, the associations between SpA disease duration and CV-related conditions were evaluated in univariable and multivariable logistic regression models. Each model examined 1 CV-related factor as dependent and {"}SpA disease duration{"} as a predictor, adjusted for relevant confounders.RESULTS: Data from 3923 subjects (median SpA disease duration 5.1 yrs, interquartile range 1.3-11.8 yrs) were available for analysis. The main CV-related conditions were hypertension (HTN; 22.4{\%}), ischemic heart disease (2.6{\%}), stroke (1.3{\%}), and diabetes mellitus (5.5{\%}). HTN was associated with SpA disease duration in both univariable and multivariable analysis, with an OR of 1.129 (95{\%} CI 1.072-1.189; p < 0.001) for each 5-year increase in SpA disease duration. Other factors associated with HTN were age, male sex, current body mass index, ever steroid therapy, and ever synthetic disease-modifying antirheumatic drug therapy, but not nonsteroidal antiinflammatory drugs (NSAID). In subgroup analysis, the strongest association of HTN and disease duration was seen in subjects with the axial-only SpA phenotype (OR 1.202, 95{\%} CI 1.053-1.372) but not in those with peripheral-only SpA (OR 0.902, 95{\%} CI 0.760-1.070). The other CV conditions were not associated with SpA disease duration.CONCLUSION: Duration of SpA disease in the ASAS-COMOSPA cohort is associated with higher odds of HTN, particularly in those with axial disease, but not with other CV-related conditions. The association with HTN does not appear to be related to NSAID exposure.",
author = "{BRITSpA and COMOSPA Investigators} and Derakhshan, {Mohammad H} and Goodson, {Nicola J} and Packham, {Jonathan C} and Raj Sengupta and Anna Molto and Helena Marzo-Ortega and Stefan Siebert",
year = "2019",
month = "1",
day = "31",
doi = "10.3899/jrheum.180538",
language = "English",
pages = "1--9",
journal = "The Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",

}

TY - JOUR

T1 - Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration

T2 - Results from the ASAS-COMOSPA Study

AU - BRITSpA and COMOSPA Investigators

AU - Derakhshan, Mohammad H

AU - Goodson, Nicola J

AU - Packham, Jonathan C

AU - Sengupta, Raj

AU - Molto, Anna

AU - Marzo-Ortega, Helena

AU - Siebert, Stefan

PY - 2019/1/31

Y1 - 2019/1/31

N2 - OBJECTIVE: Spondyloarthritis (SpA) is associated with a number of cardiovascular (CV) comorbidities. We examined the association of SpA disease duration and delay in diagnosis with CV-related conditions.METHODS: Using data from the COMOSPA study, the associations between SpA disease duration and CV-related conditions were evaluated in univariable and multivariable logistic regression models. Each model examined 1 CV-related factor as dependent and "SpA disease duration" as a predictor, adjusted for relevant confounders.RESULTS: Data from 3923 subjects (median SpA disease duration 5.1 yrs, interquartile range 1.3-11.8 yrs) were available for analysis. The main CV-related conditions were hypertension (HTN; 22.4%), ischemic heart disease (2.6%), stroke (1.3%), and diabetes mellitus (5.5%). HTN was associated with SpA disease duration in both univariable and multivariable analysis, with an OR of 1.129 (95% CI 1.072-1.189; p < 0.001) for each 5-year increase in SpA disease duration. Other factors associated with HTN were age, male sex, current body mass index, ever steroid therapy, and ever synthetic disease-modifying antirheumatic drug therapy, but not nonsteroidal antiinflammatory drugs (NSAID). In subgroup analysis, the strongest association of HTN and disease duration was seen in subjects with the axial-only SpA phenotype (OR 1.202, 95% CI 1.053-1.372) but not in those with peripheral-only SpA (OR 0.902, 95% CI 0.760-1.070). The other CV conditions were not associated with SpA disease duration.CONCLUSION: Duration of SpA disease in the ASAS-COMOSPA cohort is associated with higher odds of HTN, particularly in those with axial disease, but not with other CV-related conditions. The association with HTN does not appear to be related to NSAID exposure.

AB - OBJECTIVE: Spondyloarthritis (SpA) is associated with a number of cardiovascular (CV) comorbidities. We examined the association of SpA disease duration and delay in diagnosis with CV-related conditions.METHODS: Using data from the COMOSPA study, the associations between SpA disease duration and CV-related conditions were evaluated in univariable and multivariable logistic regression models. Each model examined 1 CV-related factor as dependent and "SpA disease duration" as a predictor, adjusted for relevant confounders.RESULTS: Data from 3923 subjects (median SpA disease duration 5.1 yrs, interquartile range 1.3-11.8 yrs) were available for analysis. The main CV-related conditions were hypertension (HTN; 22.4%), ischemic heart disease (2.6%), stroke (1.3%), and diabetes mellitus (5.5%). HTN was associated with SpA disease duration in both univariable and multivariable analysis, with an OR of 1.129 (95% CI 1.072-1.189; p < 0.001) for each 5-year increase in SpA disease duration. Other factors associated with HTN were age, male sex, current body mass index, ever steroid therapy, and ever synthetic disease-modifying antirheumatic drug therapy, but not nonsteroidal antiinflammatory drugs (NSAID). In subgroup analysis, the strongest association of HTN and disease duration was seen in subjects with the axial-only SpA phenotype (OR 1.202, 95% CI 1.053-1.372) but not in those with peripheral-only SpA (OR 0.902, 95% CI 0.760-1.070). The other CV conditions were not associated with SpA disease duration.CONCLUSION: Duration of SpA disease in the ASAS-COMOSPA cohort is associated with higher odds of HTN, particularly in those with axial disease, but not with other CV-related conditions. The association with HTN does not appear to be related to NSAID exposure.

U2 - 10.3899/jrheum.180538

DO - 10.3899/jrheum.180538

M3 - Article

SP - 1

EP - 9

JO - The Journal of Rheumatology

JF - The Journal of Rheumatology

SN - 0315-162X

ER -